# Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents

> **NCT04287387** · PHASE4 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 180 (estimated)

## Conditions studied

- Type2 Diabetes Mellitus

## Interventions

- **DRUG:** Glucophage 500Mg Tablet
- **DRUG:** Acarbose Tablets
- **DRUG:** Sitagliptin tablet
- **DRUG:** Dapagliflozin Tablet
- **DRUG:** Pioglitazone Tablets
- **DRUG:** Glimepiride Tablets

## Key facts

- **NCT ID:** NCT04287387
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-02
- **Primary completion:** 2021-03-02
- **Final completion:** 2021-03-02
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2020-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04287387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04287387, "Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04287387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*